
    
      OBJECTIVES:

        -  Assess the effects of immunomodulator arginine/omega-3 fatty acids/nucleotides oral
           supplement (Oral IMPACT®) administered via percutaneous gastrostomy during adjuvant
           chemoradiotherapy in patients with stage III or IV epidermoid head and neck cancer.

      OUTLINE: This is a multicenter study.

      Patients undergo radiotherapy 5 days a week for 6½ weeks. Patients receive cisplatin IV
      during weeks 1, 4, and 7 of radiotherapy. Patients also receive arginine/omega-3 fatty
      acids/nucleotides oral supplement (Oral IMPACT®) via percutaneous gastrostomy tube 3 times
      daily for 5 days before each chemotherapy treatment.
    
  